peoplePerson
Ruth Plummer
Ruth Plummer is an early-phase trialist who ran the first-in-human study of a PARP inhibitor.
Ruth Plummer led the first clinical trial of a PARP inhibitor (rucaparib, 2005) and directs experimental cancer medicine in Newcastle within the CRUK network.
Role
Professor of Experimental Cancer Medicine, Newcastle; Clinical Advisor, Cancer Research UK
Institution
Specialisms
Early-phase trialsDNA repair inhibitorsExperimental cancer medicine
Profiles
| Title | Journal | Year |
|---|---|---|
| Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors | Clinical Cancer Research | 2008 |
Pages like this
not linked directly; found by shared links- TrialATHENA-MONO / GOG-3020
- PathwayBase excision repair, PARP & alkylation damage
- PathwayDouble-strand break repair: HR versus end joining
- TermHomologous recombination deficiency (HRD)
- TechnologyPARP inhibitors
Shares Rucaparib, Newcastle Cancer Centre / Northern Centre for Cancer Care, PARP.
- TechnologySynthetic lethality approaches
Shares Newcastle Cancer Centre / Northern Centre for Cancer Care, PARP.